ライフサイエンスコーパス: epoxyeicosatrienoic acid

1 ase in the cardioprotective eicosanoid 14,15-epoxyeicosatrienoic acid.

2 ive in the metabolism of arachidonic acid to epoxyeicosatrienoic acids.

3 ic acid to hydroxyeicosatetraenoic acids and epoxyeicosatrienoic acids.

4 N1 and CYP2N2 metabolize arachidonic acid to epoxyeicosatrienoic acids.

5 ncluding nitric oxide, prostacyclin, and the epoxyeicosatrienoic acids.

6 logically active hydroxyeicosatetraenoic and epoxyeicosatrienoic acids.

7 2+ channels, cytosolic phospholipase A2, and epoxyeicosatrienoic acids.

8 arachidonic acid, to physiologically active epoxyeicosatrienoic acids.

9 e P450 epoxygenase, the synthetic enzyme for epoxyeicosatrienoic acids.

10 um-derived arachidonic acid metabolite 11,12 epoxyeicosatrienoic acid (11,12 EET) (300 nmol/L).

11 Because the AA metabolite 11,12-epoxyeicosatrienoic acid (11,12-EET) can inhibit the epi

12 f CYP2C23 but not CYP2J2 and increased 11,12-epoxyeicosatrienoic acid (11,12-EET) levels in isolated

13 action was enhanced by the addition of 11,12-epoxyeicosatrienoic acid (11,12-EET), a cytochrome P450-

14 peak, containing both the 11-hydroxy-14, 15-epoxyeicosatrienoic acid (11-H-14,15-EETA) and 15-H-11,1

15 We have previously reported that 14,15-epoxyeicosatrienoic acid (14, 15-EET) is a potent mitoge

16 poxygenase arachidonic acid metabolite 14,15-epoxyeicosatrienoic acid (14,15-EET) inhibits apoptosis

17 nd the molecular mechanisms underlying 14,15-epoxyeicosatrienoic acid (14,15-EET)-induced angiogenesi

18 d by the epithelial-derived eicosanoid 14,15-epoxyeicosatrienoic acid (14,15-EET).

19 yme system metabolizes arachidonate to 14,15-epoxyeicosatrienoic acid (14,15-EET).

20 proposed unstable precursor 15-hydroxy-11,12-epoxyeicosatrienoic acid (15-H-11,12-EETA).

21 5,6-Epoxyeicosatrienoic acid (5,6-EET), a proposed CIF gener

22 n was highly enantioselective for (14R, 15S)-epoxyeicosatrienoic acid (76% optical purity).

23 0 mV) in rat myocytes were inhibited by 8, 9-epoxyeicosatrienoic acid (8,9-EET) in a dose-dependent m

24 ydroxyeicosatetraenoic acid and 14(S), 15(R)-epoxyeicosatrienoic acid (80 and 20% of total products,

25 poxidizes arachidonic acid to 11,12- and 8,9-epoxyeicosatrienoic acids (80 and 20% of total metabolit

26 tive arachidonic acid epoxygenase ((14S,15R)-epoxyeicosatrienoic acid, 99% of total products).

27 We present evidence in astrocytes that 5,6-epoxyeicosatrienoic acid, a cytochrome P450 epoxygenase

28 The epoxyeicosatrienoic acid also restored the amplitude of

29 Moreover, 5,6-epoxyeicosatrienoic acid and 14,15-epoxyeicosatrienoic a

30 he osmotransducing cytosolic messenger 5'-6'-epoxyeicosatrienoic acid and allowed channel activation

31 arachidonic acid to 14,15-, 11,12-, and 8, 9-epoxyeicosatrienoic acids and 11- and 15-hydroxyeicosate

32 arachidonic acid to 14,15-, 11,12-, and 8, 9-epoxyeicosatrienoic acids and 19-hydroxyeicosatetraenoic

33 rachidonic acid into 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids and 20-hydroxyeicosatetraenoic

34 These results designate epoxyeicosatrienoic acids and EDPs as unique endogenous

35 he cytochrome P450 (cP450) pathway producing epoxyeicosatrienoic acids and hydroxyeicosatetraenoic ac

36 The role of epoxyeicosatrienoic acids and NO was assessed with the b

37 CYP4A3 metabolizes arachidonic acid to both epoxyeicosatrienoic acids and vasoconstrictive 19,20-hyd

38 2J4 convert arachidonic acid to vasodilative epoxyeicosatrienoic acids, and CYP4A3 metabolizes arachi

39 ctive products, including PGs, leukotrienes, epoxyeicosatrienoic acids, and hydroxyeicosatetraenoic a

40 Epoxyeicosatrienoic acids are endogenous constituents of

41 ubules and collecting ducts, sites where the epoxyeicosatrienoic acids are known to modulate fluid/el

42 The epoxyeicosatrienoic acids are synthesized from arachidon

43 Epoxyeicosatrienoic acids are vasodilators with anti-inf

44 id epoxygenases and that CYP2J products, the epoxyeicosatrienoic acids, are endogenous constituents o

45 Arachidonic acid-derived epoxides, epoxyeicosatrienoic acids, are important regulators of v

46 The epoxygenase products, the epoxyeicosatrienoic acids, are pro-angiogenic, and down-

47 xide, trans-diphenylpropene oxide, and 14,15-epoxyeicosatrienoic acid as substrates.

48 THETAs join prostacyclin, nitric oxide, and epoxyeicosatrienoic acids as new members of the family o

49 -dependent metabolism of arachidonic acid to epoxyeicosatrienoic acids as the principal reaction prod

50 -phorbol-12,13-didecanoate and 5,6- or 14,15-epoxyeicosatrienoic acid, as well as thapsigargin, a kno

51 unts of arachidonic, eicosapentaenoic or 8,9-epoxyeicosatrienoic acids, but some uptake persisted eve

52 in epoxidation to all four regioisomeric cis-epoxyeicosatrienoic acids (catalytic turnover 65 pmol of

53 These results show that an impaired role of epoxyeicosatrienoic acids contributes, together with an

54 ts (+/-)-8,9-, (+/-)-11,12-, and (+/-)-14,15-epoxyeicosatrienoic acid (EET) (total turnover of approx

55 We developed novel orally active epoxyeicosatrienoic acid (EET) analogs and investigated

56 synthesis of the ethyl esters of both 11,12-epoxyeicosatrienoic acid (EET) and 11S,12S-dihydroxyeico

57 of Ca2+ pools were compared; 8,9- and 11,12-epoxyeicosatrienoic acid (EET) at 1.5 microM were comple

58 In cirrhosis, 11,12-epoxyeicosatrienoic acid (EET) induces mesenteric arteri

59 r the kidney Cyp2c44 epoxygenase and for its epoxyeicosatrienoic acid (EET) metabolites in the in viv

60 s), exogenous AA induced significant 14S,15R-epoxyeicosatrienoic acid (EET) production (241.82 ng/10(

61 epoxygenases convert arachidonic acid into 4 epoxyeicosatrienoic acid (EET) regioisomers, which were

62 hibition prevents hydrolysis of the enzymes' epoxyeicosatrienoic acid (EET) substrates, so they accum

63 tography; and the results showed that 11,12- epoxyeicosatrienoic acid (EET) was the major product met

64 The CYP2J2 metabolites, 5,6-epoxyeicosatrienoic acid (EET), 14,15-EET, and the corre

65 ibition is likely a result of an increase in epoxyeicosatrienoic acid (EET)-mediated generation of RO

66 hat targeting the formation of proangiogenic epoxyeicosatrienoic acids (EET) by the cytochrome P450 a

67 Epoxyeicosatrienoic acids (EET) have antihypertensive an

68 during cirrhosis, focusing on the actions of epoxyeicosatrienoic acids (EET), known to be potent regu

69 xamined the preglomerular actions of various epoxyeicosatrienoic acids (EET).

70 aenoic acid, and leukotriene B4), TRPV4 (5,6-epoxyeicosatrienoic acid [EET] and 8,9-EET), and TRPA1 (

71 -derived metabolites of arachidonic acid the epoxyeicosatrienoic acids (EETs) and hydrogen peroxide (

72 tes biologically active compounds, including epoxyeicosatrienoic acids (EETs) and hydroxyeicosatetrae

73 ncubation with 17 mm glucose increased media epoxyeicosatrienoic acids (EETs) and reduced cell membra

74 cis-Epoxyeicosatrienoic acids (EETs) and their hydrolysis pr

75 idonic acid to 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs) and to 19- and 20-hydro

76 In bovine coronary arteries, epoxyeicosatrienoic acids (EETs) appear to function as E

77 Epoxyeicosatrienoic acids (EETs) are anti-inflammatory m

78 Epoxyeicosatrienoic acids (EETs) are cytochrome P450-epo

79 Epoxyeicosatrienoic acids (EETs) are endothelium-derived

80 Increasing endogenous levels of epoxyeicosatrienoic acids (EETs) are known for their ana

81 Epoxyeicosatrienoic acids (EETs) are major products of c

82 Epoxyeicosatrienoic acids (EETs) are potent endothelium-

83 Epoxyeicosatrienoic acids (EETs) are potent regulators o

84 Epoxyeicosatrienoic acids (EETs) are potent vasodilators

85 rachidonic acid epoxygenase metabolites, the epoxyeicosatrienoic acids (EETs) are powerful, nonregios

86 Epoxyeicosatrienoic acids (EETs) are products of cytochr

87 The epoxyeicosatrienoic acids (EETs) are products of cytochr

88 The epoxyeicosatrienoic acids (EETs) are products of cytochr

89 Epoxyeicosatrienoic acids (EETs) are small molecules pro

90 Epoxyeicosatrienoic acids (EETs) are synthesized by cyto

91 m to conduct a chemical screen, and identify epoxyeicosatrienoic acids (EETs) as a family of lipids t

92 However, AA is also converted to natural epoxyeicosatrienoic acids (EETs) by cytochrome P450 enzy

93 coronary arteries through its metabolism to epoxyeicosatrienoic acids (EETs) by cytochrome P450, we

94 CYP) epoxygenases CYP2C8 and CYP2J2 generate epoxyeicosatrienoic acids (EETs) from arachidonic acid.

95 ed from the cyclooxygenase (COX) pathway and epoxyeicosatrienoic acids (EETs) from the cytochrome P45

96 Epoxyeicosatrienoic acids (EETs) generated from arachido

97 Epoxyeicosatrienoic acids (EETs) have demonstrated antii

98 The cytochrome P450-derived epoxyeicosatrienoic acids (EETs) have potent effects on

99 Each of the four regioisomers of epoxyeicosatrienoic acids (EETs) is a candidate for bein

100 he chiral analysis of the four regioisomeric epoxyeicosatrienoic acids (EETs) is described.

101 of the CYP2B19 metabolites 11,12- and 14,15-epoxyeicosatrienoic acids (EETs) on keratinocyte transgl

102 Cytochrome P-450 (CYP)-derived epoxyeicosatrienoic acids (EETs) possess potent anti-inf

103 CYP2C50 and CYP2C54 metabolize AA to epoxyeicosatrienoic acids (EETs) primarily, and linoleic

104 Specifically, epoxyeicosatrienoic acids (EETs) produced from the P450

105 Renal cytochrome P450 (CYP)-derived epoxyeicosatrienoic acids (EETs) regulate sodium transpo

106 Endothelium-derived epoxyeicosatrienoic acids (EETs) relax vascular smooth m

107 eans to enhance the biological activities of epoxyeicosatrienoic acids (EETs) to treat cardiac hypert

108 TEs), hydroxyeicosatetraenoic acids (HETEs), epoxyeicosatrienoic acids (EETs), and dihydroxyeicosatri

109 ovascular endothelial cells, total levels of epoxyeicosatrienoic acids (EETs), but not epoxydocosapen

110 activation of KCa channels, and whether the epoxyeicosatrienoic acids (EETs), derived via cytochrome

111 zes lipid signaling molecules, including the epoxyeicosatrienoic acids (EETs), epoxidized lipids prod

112 are metabolites of arachidonic acid (AA) and epoxyeicosatrienoic acids (EETs), have been identified a

113 rachidonic acid epoxygenase metabolites, the epoxyeicosatrienoic acids (EETs), in ENaC activity have

114 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs), in inducing angiogenes

115 Epoxyeicosatrienoic acids (EETs), lipid mediators produc

116 nt in the kidney where its products, the cis-epoxyeicosatrienoic acids (EETs), modulate sodium transp

117 chrome P450 metabolites of arachidonic acid, epoxyeicosatrienoic acids (EETs), potently activate card

118 Epoxyeicosatrienoic acids (EETs), products of the cytoch

119 In this study, we investigated whether epoxyeicosatrienoic acids (EETs), the catalytic products

120 We have reported that epoxyeicosatrienoic acids (EETs), the cytochrome P450 (C

121 We have previously reported that epoxyeicosatrienoic acids (EETs), the cytochrome P450 ep

122 unds including 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs), their corresponding di

123 unds including 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs), their corresponding di

124 n the metabolism of arachidonic acid (AA) to epoxyeicosatrienoic acids (EETs), which affect multiple

125 We examined the effects of epoxyeicosatrienoic acids (EETs), which are cytochrome P

126 It serves to inactivate epoxyeicosatrienoic acids (EETs), which are generated in

127 The epoxyeicosatrienoic acids (EETs), which are products of

128 significantly attenuated in the presence of epoxyeicosatrienoic acids (EETs).

129 ses that promote the synthesis of protective epoxyeicosatrienoic acids (EETs).

130 sible for the metabolism and inactivation of epoxyeicosatrienoic acids (EETs).

131 e in the biosynthesis of eicosanoids such as epoxyeicosatrienoic acids (EETs).

132 onic acid-derived eicosanoids referred to as epoxyeicosatrienoic acids (EETs).

133 zed by cytochrome P-450 epoxygenases to four epoxyeicosatrienoic acids (EETs): 14,15-, 11,12-, 8,9-,

134 ids, including 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs); 5-, 8-, 9-, 12-, and 1

135 t in heart and active in the biosynthesis of epoxyeicosatrienoic acids (EETs); however, the functiona

136 lial metabolism (-35%, p < 0.01), vasoactive epoxyeicosatrienoic acids (EETs; -60%, p < 0.001) synthe

137 flammatory P-450 eicosanoid metabolites (cis-epoxyeicosatrienoic acids [EETs]) in the lung.

138 ality of CYP2J2 products matched that of the epoxyeicosatrienoic acid enantiomers present, in vivo, i

139 14(S),15(R)-, 11(R), 12(S)-, and 8(S),9(R)- epoxyeicosatrienoic acid enantiomers.

140 port that the 5,6-epoxide of anandamide, 5,6-epoxyeicosatrienoic acid ethanolamide (5,6-EET-EA), is a

141 droxyeicosatetraenoic acid ethanolamides and epoxyeicosatrienoic acid ethanolamides.

142 contrast, the parental arachidonic acid and epoxyeicosatrienoic acids failed to activate CB1 or CB2

143 revealed that 20-hydroxyeicosatetraenoic and epoxyeicosatrienoic acids formed by these pathways have

144 ti-inflammatory epoxy fatty acids, including epoxyeicosatrienoic acids from arachidonic acid to the c

145 as inhibition of adenosine-A2a receptors and epoxyeicosatrienoic acids had minimal effect.

146 Regio- and stereoisomeric epoxyeicosatrienoic acids have potent vasodilatory prope

147 pe channel) and to the osmotransducing lipid epoxyeicosatrienoic acid in heterologous expression stud

148 menting, for the first time, the presence of epoxyeicosatrienoic acids in human jejunum by gas chroma

149 In light of the well documented effects of epoxyeicosatrienoic acids in modulating renal tubular tr

150 was suggested by documenting the presence of epoxyeicosatrienoic acids in the human heart using gas c

151 Soluble epoxide hydrolase metabolizes epoxyeicosatrienoic acids in the vasculature and regulat

152 lites derived from omega-6 arachidonic acid, epoxyeicosatrienoic acids, increase angiogenesis and tum

153 Furthermore, local plasma epoxyeicosatrienoic acids increased during heating in co

154 ups after the Ca2+ ionophore A23187 or 14,15-epoxyeicosatrienoic acid, independent of store depletion

155 Nano- to picomolar 5, 6-epoxyeicosatrienoic acid induced [Ca2+]i elevation consi

156 hydrolase (sEH) catalyzes the conversion of epoxyeicosatrienoic acids into less active eicosanoids,

157 the cytochrome P450 epoxygenase product 5,6-epoxyeicosatrienoic acid is primarily responsible for hy

158 We have previously shown that 5, 6-epoxyeicosatrienoic acid is synthesized and released by

159 r variants in the genes that alter levels of epoxyeicosatrienoic acids is less convincing.

160 Furthermore, EET/dihydroxy-epoxyeicosatrienoic acid isomer ratios were elevated in

161 e can result in an increase in the levels of epoxyeicosatrienoic acids, leading to the attenuation of

162 In summary, our results suggest that 5,6-epoxyeicosatrienoic acid may be a component of calcium i

163 id pools in rat heart myocytes and (b) 11,12-epoxyeicosatrienoic acid may play an important functiona

164 smooth muscle and endothelium suggests that epoxyeicosatrienoic acids may also be involved in the mo

165 achidonic acid pools in human heart and that epoxyeicosatrienoic acids may, therefore, play important

166 SFZ further stimulated the production of non-epoxyeicosatrienoic acid metabolites, suggesting a metab

167 membrane phospholipids and production of non-epoxyeicosatrienoic acid metabolites.

168 In addition, cis-epoxyeicosatrienoic acid mimics the growth-suppressive a

169 ional and biological approaches, the role of epoxyeicosatrienoic acids, nitric oxide (NO)/reactive ox

170 Importantly, neither 14,15-epoxyeicosatrienoic acid nor 19-hydroxyeicosatetraenoic

171 Extracellular administration of 11, 12-epoxyeicosatrienoic acid, one of the P450-mediated metab

172 ctive with preferential formation of (8R,9S)-epoxyeicosatrienoic acid (optical purities are 91 and 90

173 2N1 and CYP2N2, respectively) and (11R, 12S)-epoxyeicosatrienoic acid (optical purities are 92 and 70

174 y, such as hydroxyeicosatetraenoic acids and epoxyeicosatrienoic acids, play novel roles in glomerula

175 The epoxyeicosatrienoic acids, products of the kidney P-450

176 city of the biological effect for the 11, 12-epoxyeicosatrienoic acid regioisomer.

177 ular tone by K(+)(Ca) channel activation and epoxyeicosatrienoic acid release and that endothelium-de

178 of K(+)(Ca) channels is only partly through epoxyeicosatrienoic acid release, indicating the presenc

179 lead to an increase in circulating levels of epoxyeicosatrienoic acids, resulting in the potentiation

180 rtholog of human CYP2J2) resulted in reduced epoxyeicosatrienoic acid synthesis.

181 used to inhibit cytochrome P450 2C9-mediated epoxyeicosatrienoic acid synthesis.

182 ted by blockade of the two critical steps in epoxyeicosatrienoic acid synthesis: release of arachidon

183 nic acid generates a series of regioisomeric epoxyeicosatrienoic acids that can be further metabolize

184 over, 5,6-epoxyeicosatrienoic acid and 14,15-epoxyeicosatrienoic acid, the cytochrome P450-dependent

185 Vitreous also contained CYP-derived epoxyeicosatrienoic acids; their levels were higher in n

186 onversion of the protective eicosanoid 14,15-epoxyeicosatrienoic acid to 14,15-dihydroxyeicosatrienoi

187 The addition of 5 microM 11, 12-epoxyeicosatrienoic acid to the perfusate prior to globa

188 poxide hydrolase catalyzes the hydrolysis of epoxyeicosatrienoic acids to dihydroxyeicosatrienoic aci

189 Soluble epoxide hydrolase converts epoxyeicosatrienoic acids to their corresponding diols,

190 ated a significantly increased production of epoxyeicosatrienoic acids, vasodilator metabolites of CY

191 When 5,6-epoxyeicosatrienoic acid was applied to the rat brain su

192 Endogenous epoxyeicosatrienoic acids were detected in both human an

193 They generate epoxyeicosatrienoic acids, which are known to have anti-

194 the epoxidation of arachidonic acid to form epoxyeicosatrienoic acids, which modulate bronchial smoo

195 osing actions of hydroxyeicosatetraenoic and epoxyeicosatrienoic acids within the vasculature.